Focus: Thermo Fisher Scientific is a $42.9B global leader in life sciences tools, diagnostics, and laboratory services serving pharma, biotech, and research sectors. The company operates across research instrumentation, clinical diagnostics, and bioproduction—a diversified model distinct from traditional drug developers.
Profile data last refreshed 22h ago · AI intelligence enriched 1mo ago
Hot — 5029 jobs added in 30d
Net +3212 (5029 new, 1817 removed). Aggressive expansion phase.
5 recent layoff filings (12 mo) — 375 affected
Source: state DOL filings via Big Local News
Ideal for infrastructure, operations, and clinical-development talent seeking stable employment at a market-leading CDMO/diagnostics player; higher risk for traditional drug researchers expecting robust pipeline investment.
Help build intelligence for Thermo Fisher Scientific
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Thermo Fisher Scientific's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
8-K Filing: Banzai International, Inc. (PARA, PARAW) (CIK 0001826011) — EXHIBIT 99.1
EXHIBIT 99.1
8-K Filing: Altimmune, Inc. (ALT) (CIK 0001326190) — 8-K
8-K
Global big pharmas are in full swing in R&D competition to capture the obesity drug and immune a.. - 매일경제
Global big pharmas are in full swing in R&D competition to capture the obesity drug and immune a.. 매일경제
Thermo Fisher Scientific launches Multiskan Ease Absorbance Microplate Reader - Select Science
Thermo Fisher Scientific launches Multiskan Ease Absorbance Microplate Reader Select Science
Thermo Fisher CEO Says AI Will Drive More Pharma Spending — Sees 7% Organic Growth By 2028 - Stocktwits
Thermo Fisher CEO Says AI Will Drive More Pharma Spending — Sees 7% Organic Growth By 2028 Stocktwits
Thermo Fisher CEO Says AI Will Drive More Pharma Spending — Sees 7% Organic Growth By 2028 - TradingView
Thermo Fisher CEO Says AI Will Drive More Pharma Spending — Sees 7% Organic Growth By 2028 TradingView
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Implementation of Nano Flow Chromatography Coupled to Mass Spectrometry as a Reliable and Sensitive Discovery Lipidomics Platform.
Content validation of the Eating Behavior and Appetite Questionnaire (EBAQ) in adolescents with obesity or overweight.
Source: state DOL filings, aggregated via Big Local News
Layoff pattern is persistent and multi-site; job security is not guaranteed despite strong headline financials—discretionary and support roles at higher risk than operations.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo